Insulin‐Like Growth Factor Binding Protein 2 Drives Neurodegeneration in Parkinson's Disease: Insights From In Vivo and In Vitro Studies
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.70076 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Jing An und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor Binding Protein 2, Oxidopamine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Insulin‐like growth factor binding protein 2 (IGFBP2) is implicated in various neurodegenerative diseases. However, its role in Parkinson's disease (PD) is unclear.
Methods
PD rat model was established by 6‐OHDA injection. After 3 weeks, mRNA‐seq was conducted. Rats received rIGFBP2 via intra‐MFB injection 6 h prior to 6‐OHDA infusion, and the effect of IGFBP2 in PD rats was investigated by western blotting, IHC, specific kits, JC‐1 staining, and TUNEL analysis. In vitro, PC12 cells were treated with 6‐OHDA, and CCK‐8, specific kits, Hoechst 33258 staining, Western blotting, and JC‐1 staining were performed to assess the IGFBP2's role. Results mRNA‐seq revealed DEGs in PD, with attention to downregulated IGFBP2. rIGFBP2 treatment aggravated neurobehavioral deficits, decreased TH expression, Ψm, ATP level and SOD, GSH‐Px activities but increased α‐synuclein, ROS, MDA, mitochondrial cytochrome c contents, cell apoptosis in 6‐OHDA‐lesioned rats, which might be mediated through inactivating IGF‐1R/AKT pathway. In 6‐OHDA‐treated PC12 cells, rIGFBP2 aggravated cell injury, demonstrated by decreased cell viability and increased apoptosis, oxidative stress, and mitochondrial dysfunction. Co‐treatment with rIGFBP2 and rIGF‐1 partially reversed the effect of rIGFBP2 on cell damage.
Conclusion
IGFBP2 exacerbates neurodegeneration in PD through increasing oxidative stress, mitochondrial dysfunction, and apoptosis via inhibiting IGF‐1R/AKT pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
ORCID-Profile: Juan Feng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
An, J., Wen, L., Yu, H., Bu, Z., & Feng, J. (2024). Insulin‐Like Growth Factor Binding Protein 2 Drives Neurodegeneration in Parkinson's Disease: Insights From In Vivo and In Vitro Studies. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70076
Vancouver
An J, Wen L, Yu H, Bu Z, Feng J. Insulin‐Like Growth Factor Binding Protein 2 Drives Neurodegeneration in Parkinson's Disease: Insights From In Vivo and In Vitro Studies. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70076
BibTeX
@article{An2024,
author = {An, Jing and Wen, Lulu and Yu, Haiyang and Bu, Zhongqi and Feng, Juan},
title = {Insulin‐Like Growth Factor Binding Protein 2 Drives Neurodegeneration in Parkinson's Disease: Insights From In Vivo and In Vitro Studies},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.70076}
}
EUVIMED